Tahoe Therapeutics
PrivateLast Round
Series A
Aug 11, 2025
Est. Valuation
$120M
Total Funding Raised
$42.25M
Company Overview
Tahoe Therapeutics is a biotechnology company that develops AI-powered models of the human cell to facilitate the design of better drugs for patients, with an initial focus on cancer.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Synthetic Data
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Foundation
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tahoe Therapeutics Comparables
Compare Tahoe Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Transcripta Bio | 82% | |
| Gordian Biotechnology | 82% | |
| Noetik | 80% |
Tahoe Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 11, 2025 | ||||
| Seed | Dec 8, 2022 |
Key People
Founding team and executive leadership
Tahoe Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Camford Capital | Seed |
| Conviction | Series A |
| General Catalyst | Series A, Seed |
| Mubadala Capital | Series A, Seed |
| Wing Venture Capital | Series A, Seed |
| Amplify Partners | Series A |
| Wing Venture Capital | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
Announced Tahoe-x1 for rapid ML model iteration.
- Jan 1, 2026
Launched Tahoe-100M, a large-scale single-cell dataset for training foundation models.
Tahoe Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Tahoe Therapeutics's valuation, stock price, and market status.
Is Tahoe Therapeutics a public or private company?
Tahoe Therapeutics is a private company.
What is the current stock price of Tahoe Therapeutics?
Tahoe Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Tahoe Therapeutics worth (valuation)?
Tahoe Therapeutics's valuation is estimated at $120.0M based on funding round data.
Can I buy Tahoe Therapeutics stock?
Tahoe Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Tahoe Therapeutics's last funding round?
Tahoe Therapeutics's most recent funding round was Series A on August 11, 2025.
Who are the main investors in Tahoe Therapeutics?
Key investors in Tahoe Therapeutics include General Catalyst, Wing Venture Capital, Amplify Partners.
Will Tahoe Therapeutics IPO soon?
No public IPO plans have been announced for Tahoe Therapeutics.
How can I track Tahoe Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Tahoe Therapeutics's secondary market activity and sign up for updates.